132 related articles for article (PubMed ID: 27699813)
1. FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
Imada K; Shiota M; Kuroiwa K; Sugimoto M; Abe T; Kohashi K; Yokomizo A; Eto M; Naito S; Oda Y
Prostate; 2017 Feb; 77(2):145-153. PubMed ID: 27699813
[TBL] [Abstract][Full Text] [Related]
2. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression.
Imada K; Shiota M; Kohashi K; Kuroiwa K; Song Y; Sugimoto M; Naito S; Oda Y
Clin Cancer Res; 2013 Sep; 19(17):4638-50. PubMed ID: 23838318
[TBL] [Abstract][Full Text] [Related]
3. The roles of Y-box-binding protein (YB)-1 and C-X-C motif chemokine ligand 14 (CXCL14) in the progression of prostate cancer via extracellular-signal-regulated kinase (ERK) signaling.
Wang C; Zhao N; Sato F; Tanimoto K; Okada H; Liu Y; Bhawal UK
Bioengineered; 2021 Dec; 12(2):9128-9139. PubMed ID: 34696665
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Saupe M; Rauschenberger L; Preuß M; Oswald S; Fussek S; Zimmermann U; Walther R; Knabbe C; Burchardt M; Stope MB
World J Urol; 2015 Oct; 33(10):1481-6. PubMed ID: 25544376
[TBL] [Abstract][Full Text] [Related]
5. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation.
Shiota M; Song Y; Yokomizo A; Kiyoshima K; Tada Y; Uchino H; Uchiumi T; Inokuchi J; Oda Y; Kuroiwa K; Tatsugami K; Naito S
Clin Cancer Res; 2010 Dec; 16(23):5654-63. PubMed ID: 21138866
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer.
Dey P; Ström A; Gustafsson JÅ
Oncogene; 2014 Aug; 33(33):4213-25. PubMed ID: 24077289
[TBL] [Abstract][Full Text] [Related]
7. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
8. Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer.
Abd El-Maqsoud NM; Osman NA; Abd El-Hamid AM; Fath El-Bab TK; Galal EM
Clin Genitourin Cancer; 2016 Apr; 14(2):e143-52. PubMed ID: 26794392
[TBL] [Abstract][Full Text] [Related]
9. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
10. Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells.
Zheng F; Wu J; Zhao S; Luo Q; Tang Q; Yang L; Li L; Wu W; Hann SS
J Exp Clin Cancer Res; 2015 May; 34(1):41. PubMed ID: 25948105
[TBL] [Abstract][Full Text] [Related]
11. Deregulation of FOXO3A during prostate cancer progression.
Shukla S; Shukla M; Maclennan GT; Fu P; Gupta S
Int J Oncol; 2009 Jun; 34(6):1613-20. PubMed ID: 19424579
[TBL] [Abstract][Full Text] [Related]
12. Platycodin D induces tumor growth arrest by activating FOXO3a expression in prostate cancer in vitro and in vivo.
Zhou R; Lu Z; Liu K; Guo J; Liu J; Zhou Y; Yang J; Mi M; Xu H
Curr Cancer Drug Targets; 2015; 14(9):860-71. PubMed ID: 25431082
[TBL] [Abstract][Full Text] [Related]
13. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
[TBL] [Abstract][Full Text] [Related]
14. Diverse effects of ANXA7 and p53 on LNCaP prostate cancer cells are associated with regulation of SGK1 transcription and phosphorylation of the SGK1 target FOXO3A.
Srivastava M; Leighton X; Starr J; Eidelman O; Pollard HB
Biomed Res Int; 2014; 2014():193635. PubMed ID: 24864229
[TBL] [Abstract][Full Text] [Related]
15. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation.
Lynch RL; Konicek BW; McNulty AM; Hanna KR; Lewis JE; Neubauer BL; Graff JR
Mol Cancer Res; 2005 Mar; 3(3):163-9. PubMed ID: 15798096
[TBL] [Abstract][Full Text] [Related]
16. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
17. NSC126188 induces apoptosis of prostate cancer PC-3 cells through inhibition of Akt membrane translocation, FoxO3a activation, and RhoB transcription.
Won KJ; Kim BK; Han G; Lee K; Jung YJ; Kim HM; Song KB; Chung KS; Won M
Apoptosis; 2014 Jan; 19(1):179-90. PubMed ID: 24085402
[TBL] [Abstract][Full Text] [Related]
18. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
19. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells.
Liu H; Yin J; Wang H; Jiang G; Deng M; Zhang G; Bu X; Cai S; Du J; He Z
Cell Signal; 2015 Mar; 27(3):510-8. PubMed ID: 25578861
[TBL] [Abstract][Full Text] [Related]
20. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway.
Yu C; Zhang Z; Liao W; Zhao X; Liu L; Wu Y; Liu Z; Li Y; Zhong Y; Chen K; Li J; Zhou F; Song L
Carcinogenesis; 2012 Mar; 33(3):678-86. PubMed ID: 22223847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]